Update: Due to Aducanumab’s New PDUFA Date, ICER Extends Timeline for Alzheimer’s Disease Assessment

Alzheimer’s disease (AD) is a fatal degenerative brain disease characterized by progressive loss of memory, cognitive skills such as language and problem-solving, and physical function. It is the most common cause of dementia in the United States (US), accounting for up to 80% of all dementia diagnoses.

Interventions of Interest:

  • aducanumab (Aduhelm™, Biogen)

Date of Review: July 2021

For questions, please contact Laura Cianciolo, Program Manager, at lcianciolo@icer.org.

View the Key Stakeholder List.